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Purpose. To evaluate the ability of frequency-doubling technology (FDT) perimetry in detecting visual field defects in young
adults with type I diabetes prior to retinopathy or with minor retinovascular changes. Methods. This comparative cross-sectional
study included 30 healthy subjects and 73 age-matched patients with type I diabetes mellitus. All subjects underwent a full ocular
examination including an FDTwith the threshold C-20-5 strategy. Only one eye per subject was randomly included in the statistical
analysis. FDT results and time to perform the test were compared between the groups. Results. The mean age was 27.1 years in
the control group and 26.6 years in the diabetic group (𝑃 = 0.875). The mean period from the onset of diabetes was 12.6 ± 6.7
years, while minimal retinovascular changes were observed in 18 eyes. Mean deviation of FDT did not differ between the groups.
Although global indices of FDT were within normal limits, pattern standard deviation of FDT was higher in the diabetic group
(𝑃 = 0.035). The area under the receiver operating characteristic curve was 0.647 for pattern standard deviation of FDT (standard
error = 0.052; 𝑃 = 0.017). Conclusion. FDT can detect retinal dysfunctions in diabetic patients prior to the onset of significant
vascular complications.
1. Introduction
Diabetic retinopathy is the major cause of visual loss in the
diabetic population, although it is not the only aspect of
visual dysfunction in these patients. There is accumulating
evidence indicating that the impairment of retinal function
precedes the earliest signs of vascular complications. Also,
functional defects have been reported in animal models of
diabetic retinopathy prior to the occurrence of any clinically
visible changes [1, 2]. Such defects are attributed to a decrease
in nerve function and consist of alterations in oscillatory
potentials, pattern electroretinogram (ERG),multifocal ERG,
S-cone ERG, and paired-flash ERG [3–10]. Other changes
include reductions in dark adaptation, visually evoked
responses, contrast sensitivity, and optic nerve conduction
velocity [11–13]. Additionally, abnormal colour sensation [14],
prolongations in visually evoked response latencies [15–22],
and defects in the retinal nerve fiber layer [23] have been
detected at stages preceding detectable retinopathy.
Some years ago, frequency-doubling technology (FDT)
perimetry was introduced, a method for assessing contrast
threshold based on the spatial frequency-doubling illusion
that occurs when a low spatial frequency sine wave grating
is counterphased at a high temporal rate, resulting in the
grating’s appearing to have twice its original spatial frequency
[24–28]. Frequency-doubling illusion does not depend on
contrast reversal and any rapid temporal variation will do
either translation or pattern onset.Thus, localized visual field
defects are tested as malfunctions of the temporal contrast
behaviour andmay contribute to the results obtainedwith the
FDT perimeter.
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White et al. [29] suggested that a cortical loss of temporal
phase discrimination is the principal cause of the illusion
and proposed that the mechanisms underlying the illusion
resemble those underlying the detection of full-field flicker,
which appears to be accomplished through themagnocellular
pathway.Therefore, FDT can be abnormal not only in patients
with visual field defects, such as those found in glaucoma,
but also in patients with impaired contrast sensitivity. The
threshold contrast, at which a pattern of stripes is just visible,
is a measure of a different visual function that can pick up
deficits in diverse pathologies including retinal diseases [11,
30–32].The reduction in contrast sensitivity found in diabetic
patients can be a source of abnormal FDT [33].
To our knowledge this is the first study aimed to evaluate
the efficacy of FDT in detecting functional impairment of
vision in patients with type I diabetes without retinopathy or
with minor retinovascular changes.
2. Materials and Methods
Thecomparative cross-sectional study protocol was approved
by the ethics committee of theMiguel Servet University Hos-
pital and written consent was obtained from all participants.
Thirty consecutive eyes of 30 healthy young adults and 73
consecutive eyes of 73 patients with type I diabetes mellitus
that met the inclusion criteria were prospectively enrolled in
the study. Control eyes were selected from patients referred
for refraction and routine exploration without abnormal
ocular findings, hospital staff, and relatives of patients of our
hospital. Diabetic patients were recruited from those referred
for annual diabetic retinopathy screening.
The following criteria were met in both groups: age
between 15 and 45 years, no cardiac diseases or uncontrolled
arterial hypertension (over 130/80mmHg), best-corrected
visual acuity of 20/30 or better (Snellen), Goldmann appla-
nation tonometry lower than 20mmHg, refractive errors
less than 5 spherical diopters and 2 cylinder diopters, and
transparent ocularmedia (nuclear color/opalescence, cortical
or posterior subcapsular lens opacity<1) according to the lens
opacities classification system (LOCS) III [34]. Subjects with
previous intraocular surgery, history of ocular or neurologic
disease, or current use of a medication that could affect
visual field sensitivity were excluded. One eye per patient was
randomly selected for the study.
Control eyes presented normal ocular findings. The fun-
duscopic examination of diabetic patient required, as a
selection criterion for this study, the absence of retinopathy
or minimal changes. The presence of five or more microa-
neurysms in each eyewas an exclusion criteria; no patient had
received previous laser treatment. The level of retinopathy
was estimated according to the early treatment diabetic
retinopathy study (ETDRS) guidelines [35].
All of them had a full ophthalmologic examination:
clinical history, visual acuity, biomicroscopy of the anterior
segment using a slit lamp, intraocular pressure, indirect oph-
thalmoscopy (evaluation of peripheral retina), and stereo-
scopic ophthalmoscopy of the posterior segment. Addition-
ally, diabetic patients underwent a blood extraction within
3 months from the subject’s date of enrolment into the study
to measure the HbA1c level.
At least 2 digital color fundus photographs with a 45-
degree field of view were acquired through dilated pupils (1%
tropicamide eye drops; Alcon Laboratories Inc., Fort Worth,
TX). One of the fundus images was centered on the fovea,
while the other was centered on the optic nerve head. The
images were evaluated by two independent observers (Isabel
Pinilla and Emilio Abecia) who were masked about the
patients’ identity and the status of disease. Any disagreement
was resolved by consensus.
FDT was performed under low ambient light using the
original frequency-doubling perimeter (Carl Zeiss Meditec,
Dublin, CA). The full-threshold C-20 strategy was used and
perimetric data were analyzed withWindows ViewFinder 1.0
software. Trial lenses and patches were not applied, but sub-
jects wore their own corrective lenses. Conditions for reliable
test were nomore than 1/6 fixation losses (16%), nomore than
1/6 false positive (16%), and no more than 1/3 false negative
responses (33%); otherwise, visual field tests were repeated.
The criterion of abnormal points for FDT was defined by the
presence of at least 5 points lower than𝑃 < 5%, 2 points lower
than 𝑃 < 2%, or 1 point lower than 𝑃 < 1% on pattern devia-
tion plot. The abnormal locations could be anywhere within
the FDT field [36]. Mean deviation (MD) and pattern stan-
dard deviation (PSD) results and time of performance of the
test were also included in the statistical analysis. Every subject
completed the FDTs prior to any other exploration, and if the
perimetry had to be repeated, it was completed in a different
day to avoid a fatigue effect.
All statistical analyses were performed using the IBM
SPSS (version 21.0; IBMCorporation, Somers, NY) andMed-
Calc (version 12.7; MedCalc software, Mariakerke, Belgium)
statistical software. The Kolmogorov Smirnov test was used
to check for a normal distribution of the data. Differences
between both groups were tested using Student’s 𝑡-test when
data followed normal distributions. The probability level at
which the null hypothesis was rejected was set at 𝑃 <
0.05.The receiver operating characteristic (ROC) curves were
plotted for the MD and PSD of FDT (bootstrap replications:
1000). The cut-off points were calculated by the MedCalc
software as the points with the best sensitivity-specificity
balance.
3. Results
3.1. Results Are Expressed as Mean ± Standard Deviation
3.1.1. Patient Data. The control group comprised 12 women
and 18 men. Their mean age was 27.1 ± 9.1 years (range: 15
to 44 years; Table 1). The diabetic group included 30 women
and 43 men; their mean age was 26.6 ± 8.3 years (range: 15
to 40 years). Figure 1 shows the funduscopic appearance of a
diabetic patient with no retinal findings and its FDT results.
The mean period from the onset of diabetes was 12.62 ± 6.7
years and the mean HbA1c was 7.78mg/dL (Table 2). In 32
of them (43.8%), the mean HbA1c value was under 7.5mg/dL
and 56.1% (41 patients) had it over this level. Better HbA1c
control was achieved in patients with higher number of
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Figure 1: Fundus photographs (one centered on the fovea and the other in the optic disc) and FDT outcome of the same patient with type I
diabetes and minor retinovascular changes.
Table 1: Demographic data and results of FDT in both study groups. 𝑃 < 0.05 was considered statistically significant (in bold print).
Control Diabetics
𝑃 value∗
Mean SD Mean SD
Age (yrs) 27.1 9.14 26.6 8.3 0.875
BCVA (Snellen) 0.93 0.1 0.94 0.1 0.645
IOP (mmHg) 14.93 2.2 14.72 2.4 0.680
FDT MD (dB) 0.25 1.52 −0.04 2.05 0.130
FDT PSD 3.43 0.39 3.78 0.95 0.035
Test time (min) 4.33 0.27 4.37 0.44 0.692
𝑛 30 73
∗Student’s 𝑡-test.
BCVA: best-corrected visual acuity; IOP: intraocular pressure; FDT: frequency-doubling perimetry; MD: mean deviation; PSD: pattern standard deviation;
SD: standard deviation.
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Table 2: Clinical data of diabetic patients.
Mean SD Minimal value Maximal value
HbA1c last 3
months 7.78 1.33 5.5 11.6
HbA1c last year 7.76 1.35 4.5 10.8
Number of insulin
injections per day 3.10 0.63 1 5
Number of insulins 2 0.55 1 4
SD: standard deviation.
insulin injections per day. According to ETDRS severity
criteria applied to our fundus photographs [35], 55 patients
had no retinopathy (level 10, 75.3%) and 18 patients (24.7%)
had microaneurysm formation only (level 20). No additional
changes were detected. Clinical data of diabetic patients are
presented in Table 2. Patients with less than 15 years of history
of diabetes were 43 (58.9%) and 30 had more than 15 years
since the diabetic onset. The age of the diabetic patients not
affected by ocular changes was lower (𝑃 < 0.001) than the age
of the patients with lesions (25.35±7.4 years versus 32.3±8.3
years, resp.). There were also differences (𝑃 < 0.001) in the
age of onset of the diabetes between patients without fundus-
copic lesions and those with minor retinovascular changes:
the mean diabetes duration was 11.06 ± 5.8 years in subjects
without retinal damage and 20.2 ± 4.2 years in patients with
minor lesions.
No significant difference was found for the factors affect-
ing retinal blood flow such as level of blood pressure, cigarette
smoking, and rheologic factors, as aspirin use, between the
groups.
3.1.2. Visual Field Data: Altered Points, MD, and PSD. MD
of FDT was not different (𝑃 = 0.13) between the control
and diabetic group (0.25 ± 1.5 dB and −0.04 ± 2.1 dB, resp.).
However, PSD of FDT differed between the groups (3.43±0.4
versus 3.78 ± 0.9 in diabetic group; 𝑃 = 0.035).
Two subjects (6.7%) of the control group and 15 (20.5%)
of the diabetic patients showed abnormal FDTs based on
the criteria of altered points. No significant differences were
observed between both groups (𝑃 = 0.09). In the diabetic
group, 12 (21.8%) of the abnormal FDT were from patients
with no retinopathy and 3 (16.7%) with minimal vascular
changes. No significant differences were observed between
the two diabetic groups (𝑃 = 0.82). Abnormal perimetries
depending on the criterion of altered points showed a
significant higher PSD value (𝑃 = 0.004) than normal tests
(4.37 ± 0.5 and 3.62 ± 1.0, resp.).
We examined whether the age of diabetes onset was
related to the FDT findings. Patients with less than 15 years
of the disease had a PSD of 3.72±0.63, while those with more
than 15 years of the disease had a PSD of 3.84 ± 1.16 (𝑃 =
0.56).There was no relationship between the HbA1c level and
the mean PSD values (3.69 ± 0.7 and 3.85 ± 1.1 in patients
with HbA1c levels lower and higher than 7.5, resp.). Neither

















Figure 2: Receiver operating characteristic (ROC) curves for MD
and PSD of FDT between healthy and diabetic patients.
The MD of FDT had an AUC of 0.580 (95% confident
interval (CI): 0.467–0.692; standard error = 0.057; 𝑃 = 0.198)
while the PSD of FDT had an AUC of 0.647 (95% CI: 0.545–
0.750; standard error = 0.052; 𝑃 = 0.017; Figure 2). The
best sensitivity-specificity balance for PSDof FDTwas 37.3%–
93.3%, respectively (cut-off point > 3.99).
3.1.3. Test Time. There were no differences in the test times
between both groups.The control group needed a mean time
of 4.33 ± 0.3 minutes to perform the perimetry and the dia-
betic group required 4.37±0.4minutes (𝑃 = 0.69). Neverthe-
less, the time to perform the FDT tests depended on the years
which passed since the diagnosis of the disease. Patients with
less than 10 years following diagnosis of diabetes required
a time of 4.21 ± 0.4 minutes, while those with more than
10 years required a time of 4.42 ± 0.5minutes (𝑃 = 0.045).
4. Discussion
Visual dysfunctions occur in diabetic patients before obvious
vasculopathy. Consequently, the vascular aberrations per se
are not necessarily the cause of the visual losses. Since retinal
neurons transduce visual signals, it follows that the loss of
neuronal function within the retina circuitry is likely to lead
to visual impairment.Diabetes is known to have a direct effect
on retinal neurons and, as a result, alterations in neuronal
function could occur soon after the beginning of the diabetes
[1, 2]. These neuropathological changes themselves may con-
tribute to the development of the diabetic retinopathy.Abnor-
malities in a wide range of electrophysiological tests have
been found before vascular anomalies were detected. The
present study explored whether the FDT would be useful for
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the individual patient in detecting such changes in neuronal
function.
FDT is a quick and efficient way of screening visual
field with a very good sensitivity and specificity [28]. This
perimetry is most likely a probe of contrast sensitivity of the
magnocellular pathway [29]. Contrast sensitivity is known to
be affected in diabetic patients and, therefore, FDT can be a
promising psychophysical test candidate for the detection of
not only glaucoma [37] but also other diseases such as dia-
betic retinopathy.
TheC-20-5 strategy tests the central 20∘ (10∘×10∘ targets),
4 per quadrantwithin the central 20∘, with one smaller central
target (5∘ diameter circle) projected on themacular region. In
our study, we used 45∘ fundus photographs centered on the
fovea and the optic disc. Consequently, they should cover the
area of the retina assessed by FDT. We did not find changes
in the number of altered FDT tests. This suggests that the
diabetic patient might not already have detectable visual field
defects.Thus, it is important to consider that the abnormality
criterion for FDT was based on glaucoma patients [36].
Hence, there will be a need for a new definition for patients
with diabetes, who are likely to have different visual field
defects than patients with glaucoma.
Although MD was similar between diabetic and normal
groups, there was a statistically significant difference in PSD
values. This suggests that localized diminutions of retinal
sensitivity occur in diabetic patients, prior to the appearance
of retinal lesions. It is relevant to note that the median age
of the diabetic group was 26 years; at this age no other optic
nerve pathologies are expected to be found. No differences
were observed between patients with normal orminimal fun-
dus changes. These can be explained for two reasons: (1) the
low number of patients affected with background retinopathy
and (2) the minimal changes they were showing. To know if
these changes can predict the appearance of retinal vascular
abnormalities in the future, a prolonged follow-up should be
performed. It is likely that those patients whose contrast sen-
sitivity was impaired later would show background retinopa-
thy. Alternatively, the test results may suggest the possibility
of an ischemic involvement; this could be controlled by tak-
ing into account angiographic findings. However, screening
normal patients with angiographies should be avoided if
possible. Parikh et al. [38] reported the possibility of using
the FDT as a way of detecting sight-threatening diabetic
retinopathy. One key difference from the present study is
that Parikh et al. included patients with advanced retinopathy
states in their study. Although their findings remain in com-
pliance with the ability of FDT in detecting ischemic states,
a crucial use of the FDT should be the ability of detecting
potential funduscopic lesions prior to their occurrence, there-
fore allowing preventive measures to be taken.
Realini et al., using the C-20-5 screening algorithm of the
FDT perimeter, have found that diabetes can affect glaucoma
screening using FDT testing and recommended the exclusion
of patients with cataract and/or diabetes from this screening,
suggesting that the specificity of the screeningwould improve
[33]. They used a suprathreshold strategy derived from the
fifth percentile of normal values, but nowadays this algorithm
is not available in the software for the commercial version of
this device. Our study has shown results based on a thres-
hold strategy that can be performed in the original commer-
cialized FDT perimeter.
Other authors reported that Matrix and scanning laser
polarimetry with variable corneal compensation (GDx VCC)
could be useful to identify early retinal impairment in
patients with type I diabetes mellitus and without signs of
retinal vasculopathy [39]. The Humphrey Matrix perime-
ter (Carl Zeiss Meditec) allows FDT algorithms similar to
those of conventional perimetry. In spite of this innovation,
the original FDT perimeter cannot be considered outdated
because each of these instruments has a different purpose.
Bell et al. [40] used themultifocal pupillographic perime-
try to evaluate changes in patients with early type 2 diabetes.
They used transient stimuli containing low spatial frequen-
cies (less than 2 cycles/degree) and found that some retinal
damage was present in the near absence of visible diabetic
retinopathy, especially in those patients with more than 10
years of diabetes.
FDT is a fast examination, ideal as a screening approach,
with an analysis time shorter than other strategies used in
standard automated perimetry. FDT testing is commonly
achieved in less than 1 minute for the suprathreshold algo-
rithm and less than 5 minutes for the threshold detecting
mode. This fact makes FDT a good option for testing visual
field in all kind of subjects, even children. Patel et al. [41]
found that subjects with normal visual fields completed the
screening C-20-1 FDT examination within 90 seconds, and
times of performance longer than 90 seconds can be consid-
ered as abnormal FDT. In our study, no significant differences
were observed for the test time between normal subjects and
the diabetic group. However, for the C-20 threshold algo-
rithm the time of the perimetry cannot be applied as amarker
of disease, because obviously the way of testing the visual
field points is different for a threshold than for a suprathresh-
old mode.
A major problem of some psychophysical tests used
for glaucoma screening such as FDT or short-wavelength
automated perimetry is the high false positive rate that would
reduce the specificity [42]. It is important to take into con-
sideration that patients with ocular pathology like cataracts
and systemic diseases such as diabetes, with orwithout retinal
manifestations, can interfere in some glaucoma screening
tests including FDT. Cataract is known to alter the contrast
sensitivity perception, and it has been demonstrated that
patients who underwent cataract extraction indeed improved
their retinal sensitivity [43].
5. Conclusions
Diabetic patients without retinopathy or with minor retino-
vascular changes have alterations in FDT threshold test with
a diminution of the sensitivity. The findings suggest the
occurrence of retinal dysfunctions prior to the onset of dia-
betic retinopathy. The test could be considered as a fast way
to determine whether there is a diminution in retinal sensi-
tivity in these patients.
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